{"name":"Biocon","slug":"biocon","ticker":"BIOCON.NS","exchange":"NSE","domain":"biocon.com","description":"Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.","hq":"Bengaluru, India","founded":0,"employees":"","ceo":"Kiran Mazumdar-Shaw (Executive Chairperson) / Siddharth Mittal (MD & CEO)","sector":"Biosimilars / Biologics","stockPrice":419,"stockChange":1.4,"stockChangePercent":0.34,"marketCap":"$7.1B","metrics":{"revenue":1757375849,"revenueGrowth":9.2,"grossMargin":60.9,"rdSpend":605000,"netIncome":-5081000,"cash":637421309.3073409,"dividendYield":12,"peRatio":147.5,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Trastuzumab patent cliff ($1.4B at risk)","drug":"Trastuzumab","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Pegfilgrastim patent cliff ($2.5B at risk)","drug":"Pegfilgrastim","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"immunology","drugs":[{"name":"Bmab1200","genericName":"Bmab1200","slug":"bmab1200","indication":"Other","status":"phase_3"},{"name":"Humulin®R","genericName":"Humulin®R","slug":"humulinr","indication":"Other","status":"marketed"},{"name":"Insulin Lispro Injection","genericName":"Insulin Lispro Injection","slug":"insulin-lispro-injection","indication":"Other","status":"marketed"},{"name":"Biocon's Human Insulin R U-500","genericName":"Biocon's Human Insulin R U-500","slug":"biocon-s-human-insulin-r-u-500","indication":"Other","status":"phase_1"},{"name":"Bmab 1000","genericName":"Bmab 1000","slug":"bmab-1000","indication":"Other","status":"phase_3"},{"name":"CARBIDOPA AND LEVODOPA","genericName":"CARBIDOPA,LEVODOPA","slug":"carbidopalevodopa","indication":"Other","status":"marketed"},{"name":"JOBEVNE","genericName":"BEVACIZUMAB-NWGD","slug":"bevacizumab-nwgd","indication":"Other","status":"marketed"},{"name":"Tregopil","genericName":"Tregopil","slug":"tregopil","indication":"Other","status":"discontinued"},{"name":"YESAFILI","genericName":"AFLIBERCEPT-JBVF","slug":"aflibercept-jbvf","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Stelara","genericName":"Stelara","slug":"stelara","indication":"Crohn's disease","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Herceptin Hylecta®","genericName":"Herceptin Hylecta®","slug":"herceptin-hylecta","indication":"HER2-positive early breast cancer (adjuvant and neoadjuvant treatment)","status":"marketed"}]}],"pipeline":[{"name":"Stelara","genericName":"Stelara","slug":"stelara","phase":"marketed","mechanism":"Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases.","indications":["Crohn's disease","Plaque psoriasis","Psoriasis","Psoriasis with arthropathy","Ulcerative colitis"],"catalyst":""},{"name":"Bmab1200","genericName":"Bmab1200","slug":"bmab1200","phase":"phase_3","mechanism":"Bmab1200 is a monoclonal antibody targeting a specific immune or disease-related antigen to modulate immune response or block pathogenic signaling.","indications":[],"catalyst":""},{"name":"Humulin®R","genericName":"Humulin®R","slug":"humulinr","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Insulin Lispro Injection","genericName":"Insulin Lispro Injection","slug":"insulin-lispro-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Biocon's Human Insulin R U-500","genericName":"Biocon's Human Insulin R U-500","slug":"biocon-s-human-insulin-r-u-500","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Bmab 1000","genericName":"Bmab 1000","slug":"bmab-1000","phase":"phase_3","mechanism":"Bmab 1000 is a monoclonal antibody targeting a specific molecular pathway, though the exact target is not publicly disclosed in available sources.","indications":[],"catalyst":""},{"name":"CARBIDOPA AND LEVODOPA","genericName":"CARBIDOPA,LEVODOPA","slug":"carbidopalevodopa","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Herceptin Hylecta®","genericName":"Herceptin Hylecta®","slug":"herceptin-hylecta","phase":"marketed","mechanism":"Herceptin Hylecta is a subcutaneous formulation of trastuzumab that binds to HER2 receptors on cancer cells to block growth signaling and trigger immune-mediated cell death.","indications":["HER2-positive early breast cancer (adjuvant and neoadjuvant treatment)","HER2-positive metastatic breast cancer","HER2-positive gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""},{"name":"JOBEVNE","genericName":"BEVACIZUMAB-NWGD","slug":"bevacizumab-nwgd","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Tregopil","genericName":"Tregopil","slug":"tregopil","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YESAFILI","genericName":"AFLIBERCEPT-JBVF","slug":"aflibercept-jbvf","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Biocon receives US FDA approval for Trastuzumab biosimilar","summary":"Biocon's Trastuzumab biosimilar has received approval from the US FDA, expanding the company's presence in the oncology market.","drugName":"Trastuzumab biosimilar","sentiment":"positive"},{"date":"2023-11-10","type":"earnings","headline":"Biocon reports strong Q3 FY2024 earnings","summary":"Biocon reported strong earnings for the third quarter of FY2024, driven by growth in its biosimilars business.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Biocon partners with Mylan to commercialize biosimilars in the US","summary":"Biocon has partnered with Mylan to commercialize its biosimilars in the US market, expanding its reach in the region.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOTmc1VFE1dzZBOVowWmE2WXJqeVJyMmMtZGxwS0ZpMEY3SnFvNHZJNnVHR0xMMmFaQkk5RmZnN0ljV1dHU0VULVZDbWxvV055N3dHUDduaU81RDN5cXh5dkFMWlB1Wk1VeFg3UVVnY0ltb2hOOFNHNXRXUmxTanU5bjdYZmNzN242RTRkRktTMGVIVXI4bGZfTXFJSGFSZHVtRkZpXzJ1OVVXOG4yakZiVjhUVllHVFBmb0dJUWVlckNUbkVRNmpkVEhQU09kQlpMWGc?oc=5","date":"2026-02-16","type":"earnings","source":"reuters.com","summary":"Biocon aims for revenue surge with rollout of generic weight-loss drugs - reuters.com","headline":"Biocon aims for revenue surge with rollout of generic weight-loss drugs","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNSWE5RURaWS1EdGo4UnZkTFZ5Y2RTTlNXTUlZVDc0aU56R1Fpblg4Wk85WnRsZ2UtdGkzSGQ0UnFTaUtDMW5lcktMTWg2M0ZxZ0c2N3Z6aHRYZ0F2U2x3VENaM3dLVG51ejI1LTVLTFBUSHBSNG44Z0Zidll0NDNXaG95YXdESk5RWG1mRGVILU9LU3c?oc=5","date":"2026-01-06","type":"patent","source":"Yahoo Finance","summary":"Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference - Yahoo Finance","headline":"Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Co","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQMmtsRFQ4MnUtZ2VSSmUyZjFOT3VaZmU5SUlRanNIaS16cDhsQkpoTGFwaExCQXdNcFNsYUxsVWNoamdfV3VZME0xb1NOWWFSd0l0RjRJZUNIVkNJd0NqRG1zaXM3UndNa2JfOTl0VFpJVU84TDA0MDBlTHpXa0pzRlk0cHc4aGNfU0tEeEo0dXY4ejFiQldFMURpMjRMZmhLdzFyY3Z2aGlDRkVrLXNuZVBzVjMwVmdKLTVGUzRmU1NXVzZkREtQMlB0UQ?oc=5","date":"2025-12-06","type":"deal","source":"reuters.com","summary":"Biocon fully integrates Biocon Biologics in $5.5 billion deal - reuters.com","headline":"Biocon fully integrates Biocon Biologics in $5.5 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1RZTA4SFo2VW5BU1VWQk5sUmw3aU5lWlRObDNHd1k0OFdoM2ZVdnhlTFJVYXAxeVBqMXNVQ3NuaGdRVTdNVTB4OU5JeGpTYk13ZmtOWThoYVk3Y29TYkE?oc=5","date":"2025-12-03","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Haleos Labs Limited (HALEOSLABS.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Haleos Labs Limited (HALEOSLABS.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPbGVNam9zX3BrVGNHTzRzaUl0UzhnbkdrS2VHYnJqcWRtbFdtUmhVVlhNckJ1UzZ5c3czaVZ5RmdiTHlMTTZTMkFhMlBmX3dsdk8wOU1ISWwtVWUxSWtkbWF0SlViVGthRmJOakFWZTNpLUxTTVVwWlhXcS1vYmhEeEoxXzJqWE9scEVVUWhnem1TUQ?oc=5","date":"2025-10-16","type":"regulatory","source":"Yahoo Finance","summary":"Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - Yahoo Finance","headline":"Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNcUczZnFiM3g1OC1JN0E4LVFsSno4ek1LdjJMTzBKSG9oZzl3dDFMc3dsLVNhaE5XZnUtd1lGV1pJV2g4RTVISUphUmNVam9UVWZfX0tDWlF5VFRZNG1vWWQ0QldsMjVRZFQ5c2JPUnkxNnMwa1ZsdnhhMHBaUmNsMkcwYzNEZw?oc=5","date":"2025-10-01","type":"patent","source":"Yahoo Finance","summary":"Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance","headline":"Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOdzNiZU5BSzd0d3dfM04xRVZvZTQzX0J0VXU0NkhpdzB4cl9SbmhpcjNGdGozaHgxSWdITXlBOXB6YXFtZFZhV2lvMDc2UE1VVllLMzVXb1l0Y2kzQ3loMjJWNzZPNHdlSXAydldXYm9UcTAtc1plUkM2NXYxd21oQkdXVDFEZVBsS3lEdXRyMFBSSFFjeU9JcWoyUHZoc2FtVk9JODYwSVhFZjkyMERMRGhvazVzQzNkSEpGbDdKQWJvdTZmYUhacnZEUVY?oc=5","date":"2025-07-31","type":"pipeline","source":"reuters.com","summary":"Trump tariffs threaten India's export edge; key sectors brace for impact - reuters.com","headline":"Trump tariffs threaten India's export edge; key sectors brace for impact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQWENqTVI0OW5xTC1aaHJFN3h6T0lneDduYzJiVzV6Z0hRNjFKaUxRTnczdllURzlWVzZHSVFoM2EtdXA0RER4LTh4R3JXeThrQjU2UWFZMFQ1ODFucy14ZWowMkgyRkxuQVJEQXJhMmlFTGxRY1Z6UWs2a1BMYl9peXU4b2J5QU1EaDdGRnNHVGFBY2ZZRjI3QnNDcXFKR3AtUTJ1aC11VG02M001bWU5T2JLTXNOVWpockoyM0JjUkdCNFBuNDJmX3VzLU9BdUMteWs3MEhOVGc5eXZPT0J5Nm13?oc=5","date":"2025-07-16","type":"patent","source":"reuters.com","summary":"Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - reuters.com","headline":"Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxObzFHV0VaRVdEaHlGNDIwa29UM2htbkhuNEprNkFHeW1uU1M3Wmp2NFFRVTUyWk9DazlSTm5iMzBkNW5iUU9wTkp0WkxCUng3eGZhNFE0V0lvbjBjcGQ4QnViSjJObHllOUVGZFkyR0JITF9zcGNsakxPenRtTkNnTHZPUlo0ZVQwQnRXTDg5blVQRDg?oc=5","date":"2025-07-15","type":"regulatory","source":"Yahoo Finance","summary":"Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - Yahoo Finance","headline":"Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Actin","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQTktKNkFndUZENm40N2Flc01hVXRtaWtJZlhJTTdJdW1KdDBqcmFfVDB0U2dLWGc1a29EOVU2ekVVdGNuZWVxMjZkMWdHQ0RZMENXTlVzMWR0bk1ReGRQVVdGX01HaFpJaDFnNUg3Zkowbk1xaEpITUNpUHNqOFViWHEzRU8zY2VHSUpHNHJmMEttQUluZ2VieVZESWgzeXBtRENJUVFvbDg2SzVZMDhULUtIRFNzQnJEb3dsc1o0LUhRank0aTRSbTBZbXVJSW1OeHdiOXZWMF9LWnc?oc=5","date":"2025-06-26","type":"pipeline","source":"reuters.com","summary":"Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market - reuters.com","headline":"Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQQmtpR0FCYW9OcnFfZDI5ODZSYTVxSGlEUUhEUjkxTDFUU1dDT2JFQVZBMlpxMlA2WExiSGJ4TWtrRnJ2aEtTamNPZGRGUDlMRUctMEZ3MjZ5eTVBWHFqSFZvcHhrSEZjNldJclI1X3NLQW9CT3NEZlc4Z3NqNWdHQXlETldadkg4LTJaTjIxR0s1aHBWU19uTlZJcWJOUzJsb1NrMlp0UmFQUWNqWVJ4R21UVzZGcE11cmROV05jRlBhel9GVWpLN28ydkE1eGludWhSWA?oc=5","date":"2024-05-20","type":"regulatory","source":"reuters.com","summary":"US FDA approves two biosimilars for blockbuster eye drug Eylea - reuters.com","headline":"US FDA approves two biosimilars for blockbuster eye drug Eylea","sentiment":"positive"},{"date":"2022-11-18","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2022-10-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2022-09-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2022-09-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"Trastuzumab","drugSlug":"herceptin","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Pegfilgrastim","drugSlug":"neulasta","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":2500000000}],"drugCount":11,"phaseCounts":{"marketed":7,"phase_3":2,"phase_1":1,"discontinued":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sandoz","Mylan","Pfizer"],"therapeuticFocus":["Oncology","Immunology","Diabetes"],"financials":{"source":"sec_edgar","revenue":40000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":40000,"period":"2019-12-31"},{"value":787000,"period":"2018-12-31"},{"value":714000,"period":"2017-12-31"},{"value":5122000,"period":"2014-12-31"},{"value":9106000,"period":"2013-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":605000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5081000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1946000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":419,"previousClose":417.6,"fiftyTwoWeekHigh":424.95,"fiftyTwoWeekLow":327.6,"fiftyTwoWeekRange":"327.6 - 424.95","fiftyDayAverage":368.84,"twoHundredDayAverage":372.92,"beta":0.23,"enterpriseValue":7568710575.977267,"forwardPE":48,"priceToBook":2.02,"priceToSales":4.03,"enterpriseToRevenue":4.31,"enterpriseToEbitda":21.65,"pegRatio":0,"ebitda":349652239.5334144,"ebitdaMargin":19.9,"freeCashflow":0,"operatingCashflow":0,"totalDebt":1726891098.5306113,"debtToEquity":50,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"2.3 - Buy","recommendationKey":"buy","numberOfAnalysts":19,"targetMeanPrice":420.63,"targetHighPrice":550,"targetLowPrice":290,"dividendRate":0.5,"payoutRatio":0.18,"fiveYearAvgDividendYield":1.16,"exDividendDate":1782950400,"insiderHeldPercent":54.1,"institutionHeldPercent":24.9,"sharesOutstanding":1619331350,"floatShares":583069055,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":2.84,"epsForward":8.73,"revenuePerShare":132.59,"bookValue":207.92,"officers":[{"age":72,"name":"Dr. Kiran  Mazumdar-Shaw B.Sc (Hons), B.Sc.","title":"Founder & Executive Chairperson"},{"age":51,"name":"Mr. Shreehas Pradeep Tambe MTech","title":"CEO, MD & Additional Director"},{"age":48,"name":"Mr. Kedar Narayan Upadhye CS, MBA","title":"Chief Financial Officer"},{"age":null,"name":"Dr. Mandar S. Ghatnekar","title":"Chief Technology Officer"},{"age":null,"name":"Mr. Saurabh  Paliwal","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Rajesh Umakant Shanoy","title":"Company Secretary & Compliance Officer"},{"age":59,"name":"Ms. Seema Shah Ahuja BA, MBA","title":"SVP & Global Head Corporate Communications & Corporate Brand Biocon Group"},{"age":null,"name":"Mr. Naveen  Narayanan","title":"Chief Human Resources Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.biocon.com","phone":"91 80 2808 2808"}}